ITMCTR2000003440招募中1 期
Efficacy and Safety Evaluation of Lingguizhugan Decoction in Treating Heart Failure With Mid Range Ejection Fraction
Hospital of Chengdu University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 75(—)
- 性别
- All
入选标准
- •1. Patients aged 18-75 years;
- •2. Newly discovered patients with chronic heart failure are treated with stable and standardized guidelines for more than 3 months;
- •3. Meet the diagnostic conditions of HFmrEF:
- •(1) Have symptoms and/or signs of heart failure;
- •(2) LVEF40%49%;
- •(3) Increased natriuretic peptide levels (B-type brain natriuretic peptide, BNP >= 35 pg/ml or N-terminal BNP precursor, NT-proBNP >=125 pg/ml)
- •(4) Related structural heart diseases: left ventricular hypertrophy (male left ventricular mass index >= 115g/m2, female >= 95g/m2) or left atrial enlargement (left atrial volume index > 34ml/m2) or diastolic dysfunction.
- •4. After more than two weeks of the washout period of Chinese medicine/Chinese patent medicine;
- •5. Heart failure caused by hypertension and underlying coronary heart disease;
- •6. Patients with cardiac function grade NYHA II/III;
- •7. Agree and sign an informed consent form.
排除标准
- •1. Heart failure is accompanied by severe heart valve disease, congenital heart disease, pericardial disease, cardiomyopathy, acute cardiovascular events in the past month, unstable angina, acute myocarditis and infective endocarditis;
- •2. Cerebrovascular accident and severe pulmonary vascular disease occurred in the last 6 months;
- •3. Severe liver and kidney dysfunction, in which creatinine > 265µmol/L
- •4. Merging serious diseases or malignant tumors of other systems;
- •5. Women who are pregnant or breastfeeding or have recent birth planning;
- •6. People with allergies, mental illnesses and infectious diseases;
- •7. Acute infection, sepsis and sepsis;
- •8. Known intolerance to long-term use of Chinese medicine;
- •9. Patients who are participating or have participated in other clinical trials within the past three months;
- •10. The investigator believes that it is not appropriate to participate in other conditions of this experiment.
研究者
相似试验
已完成
不适用
Evaluation of the efficacy and safety of luseogliflozin and changes in QOType 2 diabetes mellitusJPRN-UMIN000023035The Institute for Adult Diseases, Asahi Life Foundation64
招募中
不适用
Efficacy, safety and economic evaluation of Dangguijagyak-san for primary dysmenorrhea; a randomized, double-blind, parallel-group, multi-center, investigator-initiated clinical trialDiseases of The genitoruinary systemKCT0003005Kyung Hee University Oriental Medicine Hospital at Gangdong240
尚未招募
4 期
To evaluate the efficacy and safety of Longxiang Pingchuan capsule in the treatment of bronchial asthma with chronic duration (phlegm and stasis blocking lung syndrome)Bronchial asthmaITMCTR2200006867Dongzhimen Hospital Beijing University of Traditional Chinese Medicine
尚未招募
4 期
To evaluate the efficacy and safety of Longxiang Pingchuan capsule in the treatment of cough variant asthma (phlegm-stasis syndrome) : a multicenter, randomized, double-blind simulated, positive dCough variant asthmaITMCTR2200006869Dongzhimen Hospital Beijing University of Traditional Chinese Medicine
已完成
不适用
Evaluation of the safety and efficacy in linagliptin with type 2 diabetic patients receiving hemodialysis therapytype 2 diabetes mellitusJPRN-UMIN000010099Saitama medical University50
